MedCap (OM:MCAP) Stock EPS Growth Supports Bullish Profit Narrative After Q2 2026 Results

MedCap (OM:MCAP) has put solid numbers on the board for Q2 2026, reporting revenue of SEK619.3 million and basic EPS of SEK4.61, with trailing 12 month EPS at SEK16.07 supported by net income of SEK240.6 million on SEK2.27 billion of revenue. The company has seen revenue move from SEK1.84 billion to SEK2.27 billion over the trailing 12 month period, while basic EPS over the same span has shifted from SEK13.59 to SEK16.07. This gives investors a clear line of sight on how earnings and the top line are tracking across recent quarters as they weigh the latest release against improving margins.

See our full analysis for MedCap.

With the quarterly scorecard set, the next step is to compare these figures with the most common narratives around MedCap to see which stories the numbers support and which ones may be due for a rethink.

Curious how numbers become stories that shape markets? Explore Community Narratives

EPS trend backs profit focused story

• Basic EPS has moved from 3.37 SEK in Q1 2025 to 4.61 SEK in Q2 2026, while trailing 12 month EPS reached 16.07 SEK alongside net income of SEK240.6 million.
• What is interesting for a bullish view is that this steady EPS climb sits next to 21.1% trailing earnings growth and a 10.6% net margin, which together point to profit coming through the income statement rather than being diluted by weaker profitability.
  • Bulls who focus on MedCap as a way to gain broad exposure to Nordic healthcare companies can point to this 21.1% earnings growth alongside rising EPS as evidence that the existing portfolio has been converting revenue into profit consistently.
  • At the same time, the small step up in net margin from 10.4% to 10.6% means the bullish case is grounded in earnings quality and not just top line expansion, which fits the story of a specialist owner improving underlying businesses.

To see how this profit profile fits into the wider long term story, investors can look at what the community narrative focuses on for MedCap through the 📊 Read the what the Community is saying about MedCap..

Revenue climb to SEK619.3 million fits MedCap’s healthcare theme

• Quarterly revenue has moved from SEK498.3 million in Q1 2025 to SEK619.3 million in Q2 2026, while on a trailing 12 month basis revenue has shifted from SEK1.84 billion to SEK2.27 billion.
• Supporters of a bullish narrative often highlight MedCap as a diversified way into healthcare and assistive technology, and the rise in trailing 12 month revenue alongside 7.7% expected annual revenue growth provides numbers that can be used to argue that the underlying portfolio is adding sales while still maintaining a double digit margin.
  • The combination of SEK2.27 billion in trailing revenue and SEK240.6 million of net income shows that revenue scale has been accompanied by profitability, which helps bullish investors who care about more than just top line size.
  • Expected revenue growth of 7.7% per year compared with a Swedish market forecast where revenue is expected to decline 1.6% gives bulls a relative context, as MedCap’s portfolio companies are projected to expand sales faster than the broader market benchmark they are often compared with.

Valuation and margins line up for MedCap

• MedCap’s P/E of 35x sits below both the peer average of 50.8x and the Global Life Sciences industry average of 38.7x, while trailing net margin stands at 10.6% with earnings growth of 21.1% and a DCF fair value of SEK675.28 against a share price of SEK560.
• Supporters of the bullish side of the story can point out that this mix of profit margin and valuation metrics heavily supports the idea of a company where current pricing has not fully caught up with the earnings profile, but they also need to weigh that against their own risk work because no company specific risk items were provided here.
  • The roughly 17.1% gap between the DCF fair value of SEK675.28 and the current price of SEK560, alongside a P/E that is lower than both peers and the wider industry, is the core of that bullish valuation talking point.
  • At the same time, the 14.2% expected annual earnings growth that sits on top of a 10.6% net margin gives bulls extra support for a profit centered thesis, yet without explicit risk flags in the data, cautious investors may want to investigate portfolio concentration, healthcare regulation or private equity style leverage on their own.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on MedCap's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this upbeat tone around MedCap’s results has you interested, take a moment to review the figures yourself, compare them with your expectations, and then check the 3 key rewards

See What Else Is Out There

While MedCap shows solid earnings and revenue, the 10.6% net margin, P/E of 35x and 17.1% DCF gap may not suit investors who prefer more obvious value or income support.

If you want clearer value on your side, compare MedCap with companies in the 235 high quality undervalued stocks so you are not settling when stronger valuation support might be available.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com